The EEF2K Knockout A2780 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A2780 human ovarian epithelial carcinoma cell line. This product provides a heterogeneous pool of cells harboring targeted disruption of the EEF2K gene, offering a physiologically relevant loss-of-function model without single-cell cloning artifacts. The polyclonal format ensures retention of cellular heterogeneity, making it suitable for population-level studies of eukaryotic elongation factor 2 kinase (eEF2K) function in a cancer-relevant context.
The A2780 cell line is a well-characterized model of high-grade serous ovarian carcinoma, originally isolated from an untreated patient tumor. These cells display typical epithelial morphology and retain key oncogenic signaling pathways, including constitutive activation of the PI3K/AKT/mTOR axis. A2780 cells are extensively used to investigate ovarian cancer biology, drug responses, and mechanisms of chemoresistance, particularly to platinum-based agents. Their sensitivity to cisplatin and other chemotherapeutics makes them a valuable platform for dissecting the molecular determinants of drug sensitivity and resistance, including those involving translational control by eEF2K.
eEF2K is a calcium/calmodulin-dependent kinase that uniquely phosphorylates eukaryotic elongation factor 2 (eEF2) on Thr56, inhibiting translational elongation. This regulatory step integrates energy and nutrient status, as eEF2K is activated by AMPK-mediated phosphorylation at Ser398 and inhibited by mTORC1-dependent phosphorylation at Ser78 and Ser366. The kinase also interacts with calmodulin, Hsp90, and 14-3-3 proteins, which modulate its activity and stability. By suppressing global protein synthesis, eEF2K conserves ATP and redirects resources toward pro-survival pathways, including autophagy induction, thereby promoting cell survival under stress such as nutrient deprivation or chemotherapeutic challenge.
In the A2780 ovarian carcinoma model, EEF2K disruption provides insights into how cancer cells reprogram translation to sustain viability during metabolic stress. Ovarian tumors frequently encounter nutrient-limited microenvironments and therapeutic insults, conditions where eEF2K-mediated translation arrest may confer a survival advantage. Studies have implicated eEF2K in the regulation of autophagy and resistance to DNA-damaging agents; thus, the knockout cells enable dissection of eEF2K-dependent pathways that support ovarian cancer cell survival. This model is particularly relevant for exploring the interplay between AMPK/mTOR signaling, translational control, and autophagy in drug-resistant phenotypes.
Researchers can utilize the EEF2K Knockout A2780 Polyclonal Cells in diverse functional assays. Western blotting for phospho-eEF2 (Thr56) directly assesses eEF2K activity, while polysome profiling evaluates translational efficiency. Autophagy flux analyses using LC3-II turnover and cell viability assays under nutrient deprivation or drug treatment elucidate eEF2K??s role in stress adaptation. Metabolic flux analyses and drug sensitivity screens further characterize resistance mechanisms. For ordering and technical inquiries, please contact Ascent Research.
